Downregulation of genes involved in NFkappaB activation in peripheral blood mononuclear cells after weight loss is associated with the improvement of insulin sensitivity in individuals with the metabolic syndrome: the GENOBIN study

Diabetologia. 2008 Nov;51(11):2060-7. doi: 10.1007/s00125-008-1132-7. Epub 2008 Aug 30.

Abstract

Aims/hypothesis: The transcription factor nuclear factor-kappa-B (NFkappaB) is implicated in inflammatory responses, obesity and the metabolic syndrome, while immune cells appear to play a central role in mediating insulin resistance and can be used as a model to study inflammation and its relationship with insulin resistance. In peripheral blood mononuclear cells of overweight participants with the metabolic syndrome, we evaluated (1) the effect of diet-induced weight loss on the expression of genes involved in NFkappaB activation and (2) their association with insulin sensitivity. The genes studied were: TNF receptors TNFRSF1A and TNFRSF1B, and IL1R1, TLR4, TLR2, ICAM1, CCL5 and IKBKB.

Methods: We analysed data from 34 overweight participants with abnormal glucose metabolism and the metabolic syndrome, who were randomised to a weight-reduction (n = 24) or control group (n = 10) for 33 weeks. The mRNA expression was measured using real-time PCR. Measures of insulin and glucose homeostasis were assessed by IVGTT and OGTT.

Results: In general, the genes studied were downregulated after weight loss intervention. The changes in TLR4, TLR2, CCL5 and TNFRSF1A mRNA expression were associated with an increase in insulin sensitivity index independently of the change in waist circumference (p < 0.05). The change in IKBKB expression correlated with most of the changes in gene expression in the weight-reduction group.

Conclusions/interpretation: These results suggest that proteins encoded by CCL5, TLR2 and TLR4, and TNFRSF1A might contribute to insulin-resistant states that characterise obesity and the metabolic syndrome.

Trial registration: ClinicalTrials.gov NCT 00621205.

Trial registration: ClinicalTrials.gov NCT00621205.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Body Mass Index
  • Chemokine CCL5 / genetics*
  • Down-Regulation
  • Glucose Intolerance
  • Humans
  • Metabolic Syndrome / genetics*
  • Metabolic Syndrome / physiopathology
  • Middle Aged
  • NF-kappa B / physiology*
  • Obesity / genetics*
  • Overweight / genetics*
  • Randomized Controlled Trials as Topic
  • Receptors, Tumor Necrosis Factor, Type I / genetics*
  • Toll-Like Receptor 2 / genetics*
  • Toll-Like Receptor 4 / genetics*
  • Weight Loss

Substances

  • CCL5 protein, human
  • Chemokine CCL5
  • NF-kappa B
  • Receptors, Tumor Necrosis Factor, Type I
  • TLR2 protein, human
  • TLR4 protein, human
  • TNFRSF1A protein, human
  • Toll-Like Receptor 2
  • Toll-Like Receptor 4

Associated data

  • ClinicalTrials.gov/NCT00621205